Roger Yazbeck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2892338/publications.pdf

Version: 2024-02-01

41 papers	1,502 citations	394421 19 h-index	315739 38 g-index
42 all docs	42 docs citations	42 times ranked	2153 citing authors

#	Article	IF	Citations
1	Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2022, 13, e00452.	2.5	2
2	Breath 13CO2â€"evidence for a noninvasive biomarker to measure added refined sugar uptake. Journal of Applied Physiology, 2021, 130, 1025-1032.	2.5	1
3	Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?. Biochemical Pharmacology, 2021, 188, 114517.	4.4	25
4	Improving cost-effectiveness of endoscopic surveillance for Barrettâ€™s esophagus by reducing low-value care: a review of economic evaluations. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 5905-5917.	2.4	4
5	<scp>Costâ€effectiveness</scp> in surgery: concepts of <scp>costâ€utility</scp> analysis explained. ANZ Journal of Surgery, 2021, 91, 1717-1723.	0.7	10
6	The Effect of Isoleucine Supplementation on Body Weight Gain and Blood Glucose Response in Lean and Obese Mice. Nutrients, 2020, 12, 2446.	4.1	9
7	Breath methane to hydrogen ratio as a surrogate marker of intestinal dysbiosis in head and neck cancer. Scientific Reports, 2020, 10, 15010.	3.3	8
8	Development of a non-invasive exhaled breath test for the diagnosis of head and neck cancer. British Journal of Cancer, 2020, 123, 1775-1781.	6.4	14
9	A review of breath analysis techniques in head and neck cancer. Oral Oncology, 2020, 104, 104654.	1.5	17
10	Optimisation, validation and field applicability of a 13C-sucrose breath test to assess intestinal function in environmental enteropathy among children in resource poor settings: study protocol for a prospective study in Bangladesh, India, Kenya, Jamaica, Peru and Zambia. BMJ Open, 2020, 10, e035841.	1.9	1
11	Optimisation, validation and field applicability of a 13C-sucrose breath test to assess intestinal function in environmental enteropathy among children in resource poor settings: study protocol for a prospective study in Bangladesh, India, Kenya, Jamaica, Peru and Zambia. BMJ Open, 2020, 10, e035841.	1.9	2
12	The Use of Selected Ion Flow Tube-Mass Spectrometry Technology to Identify Breath Volatile Organic Compounds for the Detection of Head and Neck Squamous Cell Carcinoma: A Pilot Study. Medicina (Lithuania), 2019, 55, 306.	2.0	21
13	Prebiotics Fructo-, Galacto-, and Mannan-Oligosaccharide Do Not Protect against 5-Fluorouracilâ€"Induced Intestinal Mucositis in Rats. Journal of Nutrition, 2019, 149, 2164-2173.	2.9	21
14	Development of a novel 13C-labelled methionine breath test protocol for potential assessment of hepatic mitochondrial function in sheep using isotope-ratio mass spectrometry. International Journal of Mass Spectrometry, 2019, 442, 102-108.	1.5	1
15	Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity. Scientific Reports, 2019, 9, 4906.	3.3	5
16	Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein. Protoplasma, 2018, 255, 375-386.	2.1	34
17	From blood to breath: New horizons for esophageal cancer biomarkers. World Journal of Gastroenterology, 2016, 22, 10077.	3.3	37
18	In vitrodevelopment and validation of a non-invasive¹³C-stable isotope assay for ornithine decarboxylase. Journal of Breath Research, 2016, 10, 026009.	3.0	2

#	Article	IF	Citations
19	Combined Effects of Muricid Extract and 5-Fluorouracil on Intestinal Toxicity in Rats. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	1.2	15
20	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 3233-3241.	2.2	145
21	Effects ofStreptococcus thermophilusTH-4 in a rat model of doxorubicin-induced mucositis. Scandinavian Journal of Gastroenterology, 2013, 48, 959-968.	1.5	20
22	Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 313-326.	2.2	177
23	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 2075-2083.	2.2	121
24	Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis. Journal of Cellular Physiology, 2011, 226, 3219-3224.	4.1	38
25	Non-invasive detection of a palifermin-mediated adaptive response following chemotherapy-induced damage to the distal small intestine of rats. Cancer Biology and Therapy, 2011, 12, 399-406.	3.4	16
26	Dipeptidyl peptidase expression during experimental colitis in mice. Inflammatory Bowel Diseases, 2010, 16, 1340-1351.	1.9	44
27	Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis. British Journal of Nutrition, 2010, 104, 513-519.	2.3	55
28	The use of GLP-2 and related growth factors in intestinal diseases. Current Opinion in Investigational Drugs, 2010, 11, 440-6.	2.3	11
29	Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. Current Opinion in Molecular Therapeutics, 2010, 12, 798-809.	2.8	7
30	Complementary medicines: Emerging therapies for intestinal mucositis. Cancer Biology and Therapy, 2009, 8, 1629-1631.	3.4	4
31	The herbal extract IberogastÂ® improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis. Cancer Biology and Therapy, 2009, 8, 923-929.	3.4	46
32	Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biology and Therapy, 2009, 8, 505-511.	3.4	61
33	Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis.. Cancer Biology and Therapy, 2009, 8, 382-390.	3.4	72
34	Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA. Journal of Cellular Physiology, 2009, 219, 259-264.	4.1	12
35	Growth factor based therapies and intestinal disease: Is glucagon-like peptide-2 the new way forward?. Cytokine and Growth Factor Reviews, 2009, 20, 175-184.	7.2	36
36	Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends in Pharmacological Sciences, 2009, 30, 600-607.	8.7	230

#	Article	IF	Citations
37	Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU). Cancer Biology and Therapy, 2009, 8, 505-11.	3.4	4
38	Lactobacillus fermentumBR11 and Fructo-Oligosaccharide Partially Reduce Jejunal Inflammation in a Model of Intestinal Mucositis in Rats. Nutrition and Cancer, 2008, 60, 757-767.	2.0	75
39	Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Frontiers in Bioscience - Landmark, 2008, Volume, 6850.	3.0	43
40	Dipeptidyl Peptidases and Inflammatory Bowel Disease. Advances in Experimental Medicine and Biology, 2006, 575, 155-162.	1.6	11
41	Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. Journal of Cellular Physiology, 2005, 204, 687-692.	4.1	45